Phase 2 study of cabozantinib (Cabo) and pembrolizumab (Pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) resistant or refractory to immune checkpoint inhibitors (ICI).

Authors

Farshid Dayyani

University of California, Irvine Chao Family Comprehensive Cancer Center, Orange, CA

Farshid Dayyani , Joseph Chao , Fa-Chyi Lee , Thomas H. Taylor , Kristen Neumann , May T Cho

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Phase 2 study of cabozantinib (cabo) and pembrolizumab (pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) refractory to immune checkpoint inhibitors (ICIs).

First Author: Farshid Dayyani

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma.

First Author: Mark Chang

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.

First Author: Timothy Jay Price

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).

First Author: Ana Christina Garrido-Castro